Afatinib (BIBW2992)

Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM in cell-free assays, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.

Price Stock Quantity  
USD 240 In stock
USD 120 In stock
USD 210 In stock
USD 570 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Afatinib (BIBW2992) Chemical Structure

Afatinib (BIBW2992) Chemical Structure
Molecular Weight: 485.94

Validation & Quality Control

Product Use Citation(34)

Customer Product Validation(3)

Quality Control & MSDS

Related Compound Libraries

EGFR Inhibitors with Unique Features

  • Selective EGFR Inhibitor

    Erlotinib HCl (OSI-744) EGFR-selective, IC50=2 nM.

  • FDA-approved EGFR Inhibitor

    Lapatinib Approved by FDA for breast cancer.

  • Newest EGFR Inhibitor

    CO-1686 (AVL-301) Irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

  • Classic EGFR Inhibitor

    WZ4002 Mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM.

Product Information

  • Compare EGFR Inhibitors
    Compare EGFR Products
  • Research Area
  • Inhibition Profile
  • Afatinib (BIBW2992) Mechanism
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM in cell-free assays, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.
Targets EGFR (L858R) [1]
(Cell-free assay)
EGFR (wt) [1]
(Cell-free assay)
EGFR (L858R/T790M) [1]
(Cell-free assay)
HER2 [1]
(Cell-free assay)
IC50 0.4 nM 0.5 nM 10 nM 14 nM
In vitro BIBW2992 shows potent activity against both wild-type and mutant forms of EGFR and HER2. It is similar to Gefitinib in potency against L858R EGFR, but about 100-fold more active against the Gefitinib resistant L858R-T790M EGFR double mutant. BIBW2992 exhibits potent effects on both EGFR and HER2 phosphorylation in vivo. It compares favorably to reference compounds (such as Lapatinib et al.) in all cell types tested, such as human epidermoid carcinoma cell line A431 expressing wt EGFR, murine NIH-3T3 cells transfected with wt HER2, as well as breast cancer cell line BT-474 and gastric cancer cell line NCI-N87, which express endogenous HER2. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HDLM-2Mnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1n2cWlEPTB;MD6wNFU4OiEQvF2=NIXqRVVUSU6JRWK=
KASUMI-1MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIXub3hKSzVyPUCuNFA6OTFizszNNXPtfJhoW0GQR1XS
HCC2218MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEjQfmVKSzVyPUCuNFA6QDdizszNNFTHNnRUSU6JRWK=
KARPAS-45MkPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYfkSYhbUUN3ME2wMlAyPjdzIN88US=>MYXTRW5ITVJ?
HSC-4NETlVWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWPz[GZXUUN3ME2wMlAyPzR6IN88US=>NEDUbWlUSU6JRWK=
CHL-1NWLyTlFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoP4TWM2OD1yLkCxPFM6KM7:TR?=NIThT2lUSU6JRWK=
KY821NVTwR254T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEHT[nNKSzVyPUCuNFIxPiEQvF2=NHnpN4VUSU6JRWK=
NCI-N87MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnTuTWM2OD1yLkCyO|c{KM7:TR?=NHvzbpdUSU6JRWK=
DOKNUToUodJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVzJR|UxRTBwMEOxPVQh|ryPNWLI[lNMW0GQR1XS
DSH1MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2D1OmlEPTB;MD6wN|MyPCEQvF2=M1PLVnNCVkeHUh?=
MDA-MB-175-VIIM{\TTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHjNOZZKSzVyPUCuNFM1OTZizszNMljaV2FPT0WU
NCI-H2170NH3MeHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkX1TWM2OD1yLkCzO|I5KM7:TR?=MW\TRW5ITVJ?
BT-474M1TL[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVz0N|VKUUN3ME2wMlA1QTh4IN88US=>Mli4V2FPT0WU
EFO-27MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M17qemlEPTB;MD6wOVE5OiEQvF2=Mme5V2FPT0WU
NCI-H720NYD0WlN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3XUUmlEPTB;MD6wOVMzPSEQvF2=NWjTTmtSW0GQR1XS
PC-14NVnUeIEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1jpeGlEPTB;MD6wOVY3QCEQvF2=NGHrNXRUSU6JRWK=
EC-GI-10NGDHUGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUTJR|UxRTBwMEW5NVIh|ryPMYnTRW5ITVJ?
KYSE-450NE\LOYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUTJR|UxRTBwMEW5O|gh|ryPMnLxV2FPT0WU
BPH-1NV;uWnp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXf1[XFlUUN3ME2wMlA2QTh6IN88US=>NHPINHlUSU6JRWK=
NCI-H292NYHZTlBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NE\nSnJKSzVyPUCuNFYxQSEQvF2=NWGwVW5xW0GQR1XS
H9MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M33DNGlEPTB;MD6wO|E{OiEQvF2=MkHGV2FPT0WU
NCI-H526MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml3CTWM2OD1yLkC3PFI{KM7:TR?=M1PvNnNCVkeHUh?=
NCI-H1623MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1fJZ2lEPTB;MD6wPFAzPSEQvF2=NUD4V5VtW0GQR1XS
KYSE-140M1nnNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml;qTWM2OD1yLkC4N|Mh|ryPNE\zVYZUSU6JRWK=
Ca9-22MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWLJR|UxRTBwMEizOVMh|ryPNV3CPI5jW0GQR1XS
AU565MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEPTVYJKSzVyPUCuNFg2ODRizszNMWrTRW5ITVJ?
ZR-75-30MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTBwMEm1OFUh|ryPMUjTRW5ITVJ?
NCI-H1770NVPzcXJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnezTWM2OD1yLkGwNlgh|ryPMlLYV2FPT0WU
LB2241-RCCNYO1PGxOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXTJR|UxRTBwMUC4PFQh|ryPNUDQ[2x[W0GQR1XS
CAL-39M3\6e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUTJR|UxRTBwMUG3PVIh|ryPMn60V2FPT0WU
UACC-893M4P0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4DPNWlEPTB;MD6xNVg5PSEQvF2=M3\pVHNCVkeHUh?=
LU-65MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXnJR|UxRTBwMUK2N|Mh|ryPNWDDZlVNW0GQR1XS
HNNEjxWGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1;XO2lEPTB;MD6xN|A4PyEQvF2=NHW3UWRUSU6JRWK=
TI-73MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MonZTWM2OD1yLkG0O|E2KM7:TR?=NIrPfHhUSU6JRWK=
KU812NYP5TmVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV\5bVZEUUN3ME2wMlE2PDV4IN88US=>M3iyb3NCVkeHUh?=
SW13NWK4boJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWDmfldGUUN3ME2wMlE3OjF4IN88US=>MmDVV2FPT0WU
BB30-HNCMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1i2PWlEPTB;MD6xOlU4PiEQvF2=Ml60V2FPT0WU
HSC-2MnLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3X5N2lEPTB;MD6xOlg{PyEQvF2=MWrTRW5ITVJ?
BV-173NH71d2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHHpNGxKSzVyPUCuNVc2QTZizszNNEHhNmZUSU6JRWK=
CAL-27NEPITm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXjFeFhKUUN3ME2wMlE4PjN4IN88US=>M3jWW3NCVkeHUh?=
SBC-1MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVPJR|UxRTBwMUi5OVkh|ryPMVfTRW5ITVJ?
CAL-33NW\0WIY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnrDTWM2OD1yLkKwNVg1KM7:TR?=MoPZV2FPT0WU
NCI-H209MkX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1j1XGlEPTB;MD6yNFQ3KM7:TR?=MVPTRW5ITVJ?
COR-L105MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYDiPWhzUUN3ME2wMlIyODh2IN88US=>NFO3RmlUSU6JRWK=
HSC-3M1rqNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2TQNGlEPTB;MD6yNVE6QCEQvF2=NYDoS|RTW0GQR1XS
NCI-H69NFPKU49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3;EfGlEPTB;MD6yNVQ2OSEQvF2=M2DHSHNCVkeHUh?=
MOLT-13MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{XiPWlEPTB;MD6yN|k4PSEQvF2=NUDsb2FXW0GQR1XS
ML-2NFL6VItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXu3e|RIUUN3ME2wMlI1QDB{IN88US=>M2DlVnNCVkeHUh?=
IGROV-1M3[1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXfJR|UxRTBwMkW5OVIh|ryPMn;wV2FPT0WU
TK10NU\oeFJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFywd|hKSzVyPUCuNlY4OzhizszNMmHKV2FPT0WU
EoL-1-cellMnrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIPkdXRKSzVyPUCuNlY5QTJizszNM4fLSHNCVkeHUh?=
HO-1-N-1NXvv[5dNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUSycJU3UUN3ME2wMlI4QDV|IN88US=>NYOx[2RvW0GQR1XS
BHYNYX1eFQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIfw[XJKSzVyPUCuNlg3PTVizszNNWjHRm1jW0GQR1XS
LU-139M4DZemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlW3TWM2OD1yLkOwOVEh|ryPMWHTRW5ITVJ?
23132-87MkniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEXiUlFKSzVyPUCuN|E6OjNizszNMoSyV2FPT0WU
ACHNNUX5[mFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYfJR|UxRTBwM{G5PVQh|ryPMVXTRW5ITVJ?
DoTc2-4510MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4rGV2lEPTB;MD6zNlIyQSEQvF2=NFn6[ZRUSU6JRWK=
BB65-RCCNE\xXnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlT4TWM2OD1yLkO0OVk{KM7:TR?=MWjTRW5ITVJ?
HLEMo\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVTJR|UxRTBwM{WwOFYh|ryPNEC3RYVUSU6JRWK=
HCC1419NIXINXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3LqXmlEPTB;MD6zOlQxQCEQvF2=NF3DU3JUSU6JRWK=
A388NYHh[HVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2HKdmlEPTB;MD6zOlg2PyEQvF2=MVrTRW5ITVJ?
NUGC-3NYLtT5N6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX3JR|UxRTBwM{izO|Mh|ryPM2XwWXNCVkeHUh?=
KYSE-180NGLvV4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MomxTWM2OD1yLkO5NFg6KM7:TR?=MWnTRW5ITVJ?
TE-6NGHmfoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4TON2lEPTB;MD60NFI1PiEQvF2=NF\4R|BUSU6JRWK=
A498M4jWeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{T1XmlEPTB;MD60NFY4PCEQvF2=MYrTRW5ITVJ?
NCI-H1648MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVPJR|UxRTBwNESxPFIh|ryPMXfTRW5ITVJ?
DU-145NI\pOotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mm\HTWM2OD1yLkS0PFM{KM7:TR?=NVz0fmJ[W0GQR1XS
CW-2Mn;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHfqR2RKSzVyPUCuOFY6OTRizszNM1jSUXNCVkeHUh?=
A431M13TVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTBwNEiyN|Mh|ryPM4XOTnNCVkeHUh?=
SASNVrqS4JDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVnJR|UxRTBwNEizPVgh|ryPM4HkVHNCVkeHUh?=
NCI-H2126MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEDGVXJKSzVyPUCuOVE6OjZizszNMlTVV2FPT0WU
NCI-H358M3vLUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoCyTWM2OD1yLkWzNlEh|ryPMWfTRW5ITVJ?
FADUMlmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGXjfllKSzVyPUCuOVQ1ODRizszNNHjPfnVUSU6JRWK=
ACNNWK4U4VzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MonNTWM2OD1yLkW1NFk1KM7:TR?=MXrTRW5ITVJ?
HCC70NI\FWY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVvoPJZ3UUN3ME2wMlU4PjZzIN88US=>NFXLR4RUSU6JRWK=
NCI-H1838NVLzTJNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX3JR|UxRTBwNkCyPVkh|ryPMVPTRW5ITVJ?
CAL-54NFq3TlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NELIV2hKSzVyPUCuOlE3OjFizszNM1:xbXNCVkeHUh?=
NCI-H1975MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWHJR|UxRTBwNkG3Nlgh|ryPNW\v[It6W0GQR1XS
COR-L88NW\ZRoZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1ix[WlEPTB;MD62OFEyOyEQvF2=NH7rSG1USU6JRWK=
CTV-1NFj2R41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVHMR2FLUUN3ME2wMlY1Ozl{IN88US=>M4TqSXNCVkeHUh?=
EW-18NHywNlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWnRcXJkUUN3ME2wMlY5Pjl6IN88US=>MnrxV2FPT0WU
HCC1806MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYXKc3JnUUN3ME2wMlY6PjZ4IN88US=>MXjTRW5ITVJ?
HuP-T4NVHUWYQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXjJR|UxRTBwNkm3OkDPxE1?MWPTRW5ITVJ?
MDA-MB-361NUnGXZZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnvCTWM2OD1yLkeyOlYzKM7:TR?=MY\TRW5ITVJ?
NCI-H1573NF\NU25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX;JR|UxRTBwN{O2N{DPxE1?NVHZSWNoW0GQR1XS
KU-19-19MkS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXLJR|UxRTBwN{e0OlQh|ryPMVXTRW5ITVJ?
COLO-678NFnwSoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3rPUmlEPTB;MD64NFg{PCEQvF2=M37Bd3NCVkeHUh?=
C-33-AM17ZTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFyzfotKSzVyPUCuPFEzQTdizszNMWHTRW5ITVJ?
Calu-3MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1fLcWlEPTB;MD64NVQ{PCEQvF2=M3mz[XNCVkeHUh?=
AGSMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlLSTWM2OD1yLkizOlQ5KM7:TR?=MV;TRW5ITVJ?
SCC-25NGXiSY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGruXGFKSzVyPUCuPFQyPzFizszNMoHOV2FPT0WU
JVM-2M4HROGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTBwOEiyPVkh|ryPNGf6fYZUSU6JRWK=
HCE-TM2LwPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVfJR|UxRTBwOEi0Nlgh|ryPMVrTRW5ITVJ?
ES4MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGnJ[4ZKSzVyPUCuPVc5OzZizszNM1nNS3NCVkeHUh?=
EKVXMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlzjTWM2OD1zLkCxNFY1KM7:TR?=M3P1VHNCVkeHUh?=
D-542MGMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2H0[mlEPTB;MT6wNVA3PCEQvF2=Ml7WV2FPT0WU
SW1116NVfYeVhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEK0elNKSzVyPUGuNFEzQDdizszNNUXQWJA5W0GQR1XS
5637NH:0dJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4XEemlEPTB;MT6wNVUyKM7:TR?=MX\TRW5ITVJ?
HT-1376M2fQe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWnkW4E4UUN3ME2xMlAyPTF|IN88US=>NVXBNJdHW0GQR1XS
NB69MmfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NE\6NWJKSzVyPUGuNFI6PDVizszNNUTicVJsW0GQR1XS
YKG-1MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTFwMEW0NVkh|ryPNFnuR41USU6JRWK=
EW-3Mn\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX3JR|UxRTFwMEe4PFMh|ryPNGTnbI5USU6JRWK=
GCIYNInOdGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml:xTWM2OD1zLkC4NVA1KM7:TR?=NVzOO415W0GQR1XS
SK-MES-1NFrJfVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkfMTWM2OD1zLkGxOFg4KM7:TR?=M3jHNXNCVkeHUh?=
PANC-08-13NFPENo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHHGN|ZKSzVyPUGuNVY1OTZizszNNWnnUopQW0GQR1XS
SK-NEP-1MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mmi4TWM2OD1zLkG3OVE{KM7:TR?=NXXlfpdNW0GQR1XS
SW954NXXUSnBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1nh[GlEPTB;MT6yNFIyPCEQvF2=M4XnO3NCVkeHUh?=
NCI-SNU-5M1;SWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoPNTWM2OD1zLkKzPUDPxE1?NUX3ZW4{W0GQR1XS
SW48NX3mTGJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3zBNGlEPTB;MT6yOVQ{OiEQvF2=NUTSfJljW0GQR1XS
HT-3M4\MVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYHFS4ZuUUN3ME2xMlI5PzV|IN88US=>MVzTRW5ITVJ?
ETK-1MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NILoOWtKSzVyPUGuN|c1PTZizszNMmnnV2FPT0WU
SCC-15M{Xre2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGrK[IhKSzVyPUGuN|k1PTFizszNNVXZbmM6W0GQR1XS
DU-4475M{PybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWPFTodsUUN3ME2xMlQxOTJzIN88US=>NFu0cpFUSU6JRWK=
NB5M2LZOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYHJR|UxRTFwNEGzNVch|ryPMUfTRW5ITVJ?
CFPAC-1M2Hjemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NULrOJNbUUN3ME2xMlQzPDl|IN88US=>MlOwV2FPT0WU
NCI-H630MnqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkPETWM2OD1zLkS1OVgzKM7:TR?=NVXMepQ{W0GQR1XS
NCI-H82MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{n6NGlEPTB;MT61OFAxPiEQvF2=MUjTRW5ITVJ?
ECC10MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXHLU5lOUUN3ME2xMlU2OzZ7IN88US=>NF;H[JdUSU6JRWK=
K5NFHsVm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NITrR5VKSzVyPUGuOVg{PTdizszNM37TenNCVkeHUh?=
ME-180MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{PLe2lEPTB;MT62NVA6PiEQvF2=NFfvc4JUSU6JRWK=
KYSE-410M1TNdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkPHTWM2OD1zLk[1OlczKM7:TR?=M1HYfXNCVkeHUh?=
G-401MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFXZXFhKSzVyPUGuOlc1OTNizszNNUHle4pVW0GQR1XS
TGBC24TKBNEDJd4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGXhe4ZKSzVyPUGuOlgzOyEQvF2=NIDLTGRUSU6JRWK=
Detroit562MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV;jSJpZUUN3ME2xMlcxOTV{IN88US=>MlnQV2FPT0WU
OE19MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTFwN{G1NVIh|ryPNFSxXW5USU6JRWK=
CAKI-1MorpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVfJR|UxRTFwN{iyNVEh|ryPM36ydXNCVkeHUh?=
TE-12NVPF[lNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{DQV2lEPTB;MT64NFQyPCEQvF2=NYXLcIhCW0GQR1XS
NCI-H1666M{PzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRTFwOEC5OFgh|ryPNILUT|FUSU6JRWK=
TE-1MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEe0TIVKSzVyPUGuPFE1PzVizszNNHzjcWRUSU6JRWK=
CAL-12TNGTE[JpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmKwTWM2OD1zLki4PVQ2KM7:TR?=MWTTRW5ITVJ?
TE-8M4fkXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYrJR|UxRTFwOUGzO|ch|ryPM{LOTHNCVkeHUh?=
KYSE-270NIG1RZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnfnTWM2OD1{LkCyO|MzKM7:TR?=Mm\6V2FPT0WU
GMS-10NX73dopvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXXJR|UxRTJwMEO1NVch|ryPNHjSb|NUSU6JRWK=
A2780MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV3JR|UxRTJwME[yPVQh|ryPNHjsdpRUSU6JRWK=
OMC-1MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mm\rTWM2OD1{LkC4NVY6KM7:TR?=MlHWV2FPT0WU
LoVoMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHSNYh1UUN3ME2yMlExPzl5IN88US=>M4PPbXNCVkeHUh?=
PANC-03-27NFy4U4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmDFTWM2OD1{LkG2OlMyKM7:TR?=M{XGOHNCVkeHUh?=
MDA-MB-157MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml3JTWM2OD1{LkKxPFI5KM7:TR?=NYnxfoF[W0GQR1XS
CaR-1M3rYcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml7MTWM2OD1{LkK4NlgyKM7:TR?=NWK0SJNGW0GQR1XS
769-PMlPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWXJR|UxRTJwMkmwN|ch|ryPM3nXcHNCVkeHUh?=
NB7MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoDCTWM2OD1{LkK5Olc3KM7:TR?=NEHN[HJUSU6JRWK=
MKN7NFLj[W9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX\JR|UxRTJwM{WzN|Uh|ryPNGLRTFNUSU6JRWK=
NCI-H1048NWrQ[WtqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NImwTpJKSzVyPUKuOFkyPThizszNMUnTRW5ITVJ?
RCM-1NXHocJhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3H6W2lEPTB;Mj61Nlk{QCEQvF2=NXrKRpRoW0GQR1XS
HT55MkH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUDVWpR1UUN3ME2yMlU4OzhizszNNELvUWZUSU6JRWK=
HCC1569Mn\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTJwNUiyPVch|ryPMofsV2FPT0WU
LXF-289M{P4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2KxcWlEPTB;Mj62N|U3PSEQvF2=MUnTRW5ITVJ?
OVCAR-3M3\IN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkLCTWM2OD1{Lk[3NVY4KM7:TR?=M3j5WHNCVkeHUh?=
TE-10Mln6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGntWYxKSzVyPUKuOlgxPzhizszNM3;oOnNCVkeHUh?=
SNU-C2BNGGybZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYK1TXlUUUN3ME2yMlY5PjF4IN88US=>NHflU2pUSU6JRWK=
LB1047-RCCM1fzPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYTJR|UxRTJwN{S4PFgh|ryPM4L0NXNCVkeHUh?=
SN12CNVXpXHlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4K0dWlEPTB;Mj65NVk3PCEQvF2=NYjKNmVPW0GQR1XS
786-0NI\wV4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGXYTFZKSzVyPUOuNFY1ODhizszNMmXLV2FPT0WU
HT-29NYmyTXUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFi5[HNKSzVyPUOuNFc{ODlizszNMm[wV2FPT0WU
RPMI-7951MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXX5ephPUUN3ME2zMlA4PTlizszNMn;vV2FPT0WU
NBsusSRMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUDJR|UxRTNwMUiyOVQh|ryPM2PHfnNCVkeHUh?=
NKM-1NX:2N|luT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1PxXWlEPTB;Mz6xPFc1PCEQvF2=NIj2R3FUSU6JRWK=
Capan-2NVjaOFVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnLrTWM2OD1|LkS2PFc2KM7:TR?=M2Tmb3NCVkeHUh?=
MKN1NYXWUpc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2T3PWlEPTB;Mz60O|ExQCEQvF2=M1rxeHNCVkeHUh?=
OAW-42NHfvW|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXvxOnNMUUN3ME2zMlUxODJ4IN88US=>MYHTRW5ITVJ?
SKG-IIIaMmHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{TXb2lEPTB;Mz61NlI{PyEQvF2=NUPUXWpXW0GQR1XS
no-11NIjOS3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH\0RZhKSzVyPUOuOVM2PjRizszNMoX5V2FPT0WU
NYMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXv6cWtkUUN3ME2zMlU{PjV3IN88US=>MkTJV2FPT0WU
HEC-1MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2HOcGlEPTB;Mz61PFk2KM7:TR?=MY\TRW5ITVJ?
NCI-H441M3XSRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHXV[mNKSzVyPUOuOVk5PDFizszNMnnVV2FPT0WU
NCI-H2009MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn7PTWM2OD1|Lk[xNlE3KM7:TR?=MoKwV2FPT0WU
T47DMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUnQSXFyUUN3ME2zMlYzOjF5IN88US=>NUjibJNNW0GQR1XS
SNU-449NYLCSI1zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\1c|FEUUN3ME2zMlY2QDJ4IN88US=>M4ewN3NCVkeHUh?=
NCI-SNU-1M{nLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnGzTWM2OD1|Lk[5O|M2KM7:TR?=MWnTRW5ITVJ?
BT-20MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUTJR|UxRTNwNkm3PVUh|ryPMUfTRW5ITVJ?
LS-123NIfMUXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1nRTmlEPTB;Mz63OFI5PCEQvF2=NUnTU4RyW0GQR1XS
8305CNXTUSpNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYjlOodmUUN3ME2zMlc2QTFzIN88US=>M3O3dnNCVkeHUh?=
OCUB-MNF[zOG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1n6WWlEPTB;Mz63OlE5PyEQvF2=NH\hXoVUSU6JRWK=
KOSC-2NXnnOIVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlL2TWM2OD1|LkizOFUyKM7:TR?=MXvTRW5ITVJ?
NCI-H1693MoPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml7FTWM2OD1|Lki0NVgyKM7:TR?=M3rCd3NCVkeHUh?=
TE-9MmH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUf3NZB6UUN3ME2zMlg1Ozh{IN88US=>NUPyNZU2W0GQR1XS
MV-4-11M3fJbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVnJR|UxRTNwOEe5PVQh|ryPNYrxN2VFW0GQR1XS
GAMGMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlnNTWM2OD1|LkmxN|E1KM7:TR?=NXPUTZBkW0GQR1XS
KNS-62NEPmdnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1fzOWlEPTB;Mz65OFc{OSEQvF2=NEDHVHNUSU6JRWK=
MC116NHvEZlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXu0Z4Y6UUN3ME2zMlk2PDh7IN88US=>NGrh[JZUSU6JRWK=
647-VMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIXqPWxKSzVyPUOuPVg1PTJizszNMXLTRW5ITVJ?
U-87-MGMnXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV;JR|UxRTRwMUC0PFEh|ryPM2DnR3NCVkeHUh?=
RPMI-8226MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnHFTWM2OD12LkGxOlMyKM7:TR?=MmP6V2FPT0WU
SW1417M{\1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmDRTWM2OD12LkGyNVQ4KM7:TR?=MYnTRW5ITVJ?
LAMA-84M3y3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\oTWM2OD12LkG3NFIh|ryPM{O1eXNCVkeHUh?=
LS-513MnHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUDCXWVIUUN3ME20MlMyOjF5IN88US=>NUPtVllCW0GQR1XS
KLENUjFOIZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NI\KO25KSzVyPUSuOFA5OTlizszNNUDrd5dTW0GQR1XS
HCT-116NUnnWlQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGTZd3RKSzVyPUSuOFExODdizszNMoTFV2FPT0WU
EPLC-272HMkXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWHJR|UxRTRwNEG1N|Mh|ryPMl;LV2FPT0WU
KS-1NVv3VGRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M13hSmlEPTB;ND61NFg5QSEQvF2=MojmV2FPT0WU
HT-1197NIHRe4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3Xoe2lEPTB;ND61NlY3QSEQvF2=NGjZXYVUSU6JRWK=
LCLC-97TM1NHjyc4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU[4cHVrUUN3ME20MlU{Pjh4IN88US=>NWD6PVROW0GQR1XS
ES5M4DV[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVKzbJgzUUN3ME20Mlg{PzJ|IN88US=>NULDZVZrW0GQR1XS
CTB-1MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVXJR|UxRTRwOES4PEDPxE1?NIjWXIVUSU6JRWK=
HL-60NWHGTlk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk\DTWM2OD12Lki2OlEyKM7:TR?=NWXkPIRiW0GQR1XS
VM-CUB-1MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTRwOE[4NVkh|ryPMXrTRW5ITVJ?
MEG-01MmTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVXOSGd1UUN3ME20Mlk6PDB|IN88US=>M2DGSXNCVkeHUh?=
KYSE-520M4rBemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml:zTWM2OD13LkKwPFM6KM7:TR?=NViyS4wzW0GQR1XS
HuO-3N1Mnz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkfmTWM2OD13LkK0NFQ{KM7:TR?=Ml7lV2FPT0WU
SW620MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWXkPWlJUUN3ME21MlI1QTZ2IN88US=>NUnoW4JjW0GQR1XS
U031NWfjdWdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\kSGlEPTB;NT6yOVQzPCEQvF2=MYXTRW5ITVJ?
TE-5MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV3JR|UxRTVwNEC4OUDPxE1?MXnTRW5ITVJ?
NCI-H747NI\UPHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoOyTWM2OD13LkSyOFczKM7:TR?=NXLyU|d5W0GQR1XS
MG-63MoHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWXJR|UxRTVwNEi3OlIh|ryPNU\VVW5nW0GQR1XS
HC-1NFu5cWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnXUTWM2OD13LkWxPFM6KM7:TR?=NVHmOWF4W0GQR1XS
HCC2998MnvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoXsTWM2OD13LkWyOlE2KM7:TR?=MXrTRW5ITVJ?
NTERA-S-cl-D1NUntT5YyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF;wXmVKSzVyPUWuOVQ2OzdizszNNFPnPHpUSU6JRWK=
KINGS-1MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEnERlBKSzVyPUWuOlA6PDRizszNMUDTRW5ITVJ?
D-423MGMnLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFPhe2VKSzVyPUWuOlE4ODVizszNNHjBRXpUSU6JRWK=
SW962M1LaWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGr4bHpKSzVyPUWuOlIxOzJizszNM4DYZ3NCVkeHUh?=
LOXIMVIMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVjDcWhWUUN3ME21MlY{QDd|IN88US=>NGXFbFdUSU6JRWK=
LS-411NMkjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkLFTWM2OD13Lke5OFQyKM7:TR?=NIXXVoRUSU6JRWK=
NCI-H2291NWHt[HY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{jCdGlEPTB;NT65PFk1OyEQvF2=NYLPOWdRW0GQR1XS
A549NInQT3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{H4TWlEPTB;Nj6xNlU2OyEQvF2=MmXyV2FPT0WU
LS-1034NHf3[FZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYnJR|UxRTZwMkC3NFYh|ryPMXPTRW5ITVJ?
NB14MmTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRTZwNEO4N|Yh|ryPMn\BV2FPT0WU
NCI-H1299Ml:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{jpOWlEPTB;Nj62N|E4OSEQvF2=MoTUV2FPT0WU
BT-549MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVjJR|UxRTZwNk[4PFkh|ryPMVfTRW5ITVJ?
J-RT3-T3-5NVHUSo1vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV7JR|UxRTZwOE[5JO69VQ>?M1flRnNCVkeHUh?=
SW756MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVHJR|UxRTZwOUGxO|Yh|ryPMVvTRW5ITVJ?
DJM-1NIHEe5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX7id29uUUN3ME22MlkzODF{IN88US=>NInLc4tUSU6JRWK=
GP5dMlTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH\NU5pKSzVyPU[uPVc{QTRizszNMnLqV2FPT0WU
MOLT-4MorrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIiyTWdKSzVyPUeuNFIyOzVizszNNG\UOVBUSU6JRWK=
NCI-H28NXXEZ3FVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV7JR|UxRTdwMU[0NFUh|ryPNXq5VHV[W0GQR1XS
MN-60Mn[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{\6bGlEPTB;Nz6yPFA5QSEQvF2=NIX6eYRUSU6JRWK=
RMG-INHy0[JRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTdwM{myPVYh|ryPNW\1SFl6W0GQR1XS
COLO-800NEi4XmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU\T[XZZUUN3ME23MlQyPDR4IN88US=>NUTIdYw5W0GQR1XS
DBMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXPpXFZIUUN3ME23MlYyODB3IN88US=>NXzUO5pUW0GQR1XS
Ca-SkiM{SyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrKTWM2OD15Lk[0NlU6KM7:TR?=M{XtdXNCVkeHUh?=
HELM1WwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{TDcGlEPTB;Nz63NVIxOyEQvF2=MWPTRW5ITVJ?
NH-12NGi5dZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NET1b4tKSzVyPUeuO|I5ODhizszNMWfTRW5ITVJ?
LB373-MEL-DNVqyWmtpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWnJR|UxRTdwN{[3O|Eh|ryPM{fZd3NCVkeHUh?=
SW900NFO2WpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk\6TWM2OD15LkiyNVIyKM7:TR?=M373W3NCVkeHUh?=
JVM-3NVnHSZZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml76TWM2OD15Lki5OVk6KM7:TR?=Mn3qV2FPT0WU
OAW-28MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NG\SepBKSzVyPUeuPVQ2PzhizszNNVvSRWF{W0GQR1XS
KURAMOCHINYjHfIp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn;BTWM2OD15Lkm0PFEyKM7:TR?=MlfOV2FPT0WU
BE-13NFKy[olIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mmf0TWM2OD15Lkm4NVEzKM7:TR?=NWfncJI{W0GQR1XS
VMRC-RCZM1rSc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4nDS2lEPTB;OD6wNVY6PyEQvF2=MoHRV2FPT0WU
NCI-H727M3y1dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVrJR|UxRThwMUC0NkDPxE1?NIrHZ|dUSU6JRWK=
SW1710NVnHTY5JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M17oZmlEPTB;OD6xPFUyPSEQvF2=MX\TRW5ITVJ?
D-502MGNV3CO2k6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1O3SmlEPTB;OD6yPVI5OiEQvF2=NFnwenFUSU6JRWK=
NCI-H1993M2jTNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{\CVmlEPTB;OD6zN|Y{OSEQvF2=MofRV2FPT0WU
SCC-4M3HPO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2fON2lEPTB;OD60OFA2QSEQvF2=MULTRW5ITVJ?
HAL-01NXqwPY5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NET1THZKSzVyPUiuOVE6OSEQvF2=MkLBV2FPT0WU
GT3TKBNWXsdHVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUOzXJVrUUN3ME24MlY4QTZ2IN88US=>M3TCZnNCVkeHUh?=
SK-OV-3MorZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1LOVWlEPTB;OD63NVMzQSEQvF2=NWLsc|hJW0GQR1XS
COLO-829MkCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXm3VYJCUUN3ME24MlgxQTd4IN88US=>NUfMV3VIW0GQR1XS
OCI-AML2NUTSeGs5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{KyWWlEPTB;OD65OVQ5OSEQvF2=NF7YXlRUSU6JRWK=
OS-RC-2M{LEeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmO4TWM2OD17LkCyNVkh|ryPMojjV2FPT0WU
BFTC-909M13W[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3TjTWlEPTB;OT6wOlc6QSEQvF2=MXLTRW5ITVJ?
EW-11NEDMT4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mlr0TWM2OD17LkG3OlU{KM7:TR?=MWfTRW5ITVJ?
HCE-4MkfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkfkTWM2OD17LkKxOVU5KM7:TR?=NXfpb5BxW0GQR1XS
BALL-1M3e5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWfJR|UxRTlwMkG5NFch|ryPMkH3V2FPT0WU
SF539NIm1W4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{SwdmlEPTB;OT6yN|U3OiEQvF2=MonMV2FPT0WU
CAMA-1MkHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmriTWM2OD17LkK4NVI5KM7:TR?=MW\TRW5ITVJ?
C32M{ToUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYDD[nAxUUN3ME25MlM{ODZ2IN88US=>NEX3NnlUSU6JRWK=
NCI-H1703MnnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnfvTWM2OD17LkO0N|c2KM7:TR?=NGnUVlFUSU6JRWK=
NCI-H1650NGnXWGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVPJR|UxRTlwNkC5OFYh|ryPNVrGVYxRW0GQR1XS
NCI-H1563NF62SVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlfvTWM2OD17Lke2NFMyKM7:TR?=NIH4RXdUSU6JRWK=
CAL-85-1M2f3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXvBUFNsUUN3ME25Mlg4Ozh|IN88US=>NIL0bGlUSU6JRWK=
UM-UC-3NWP6Z4c2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF;DSXdKSzVyPUmuPVUxOyEQvF2=NXvCNlNCW0GQR1XS
BxPC-3M2nDbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2PaeWlEPTB;MUCuNFk4OiEQvF2=MULTRW5ITVJ?
MHH-PREB-1NIHYTJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHzDUm9KSzVyPUGwMlE6QTlizszNMYfTRW5ITVJ?
DELMlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXXxfmJxUUN3ME2xNE4{QTR4IN88US=>MnnHV2FPT0WU
HuCCT1NGjKcWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkTjTWM2OD1zMD62NFM{KM7:TR?=MXTTRW5ITVJ?
OVCAR-4Mlq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnK5TWM2OD1zMD64PFM2KM7:TR?=NX7aZmVnW0GQR1XS
CAL-72NIfwZZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYHGNZlXUUN3ME2xNE46OzlzIN88US=>M3n5S3NCVkeHUh?=
HCC1954NWDReWF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnjRTWM2OD1zMT6wO|U1KM7:TR?=NUHURnJQW0GQR1XS
EFO-21Mn3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXzJR|UxRTFzLkGwOFUh|ryPMVXTRW5ITVJ?
FTC-133MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVPJR|UxRTFzLkG0NFch|ryPM4\vfnNCVkeHUh?=
SK-MEL-24Moq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYPJR|UxRTFzLkKzOlYh|ryPNInwbW5USU6JRWK=
UACC-62NILIO4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYrOT|hzUUN3ME2xNU4zOzZ6IN88US=>NF;qTlRUSU6JRWK=
NCI-H650NILCbmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M17FTmlEPTB;MUGuNlQyQCEQvF2=MoHLV2FPT0WU
ALL-POMUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1yxemlEPTB;MUGuNlUyOiEQvF2=NES0V2xUSU6JRWK=
T84MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3TQZmlEPTB;MUGuN|kxPyEQvF2=MX;TRW5ITVJ?
IST-MEL1NI\4PJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIrUelVKSzVyPUGxMlQ2PTlizszNNEjvVWdUSU6JRWK=
SW626NYLVXnI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYfJ[HNLUUN3ME2xNU42PzV3IN88US=>M4i0b3NCVkeHUh?=
RPMI-2650MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4C1[2lEPTB;MUGuOVg5PSEQvF2=MXvTRW5ITVJ?
MC-IXCM3TvWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV7iWJpCUUN3ME2xNU43PzJ6IN88US=>NV65bGRqW0GQR1XS
HOP-62MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MULJR|UxRTFzLk[3OlQh|ryPMlvyV2FPT0WU
NOS-1MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2exTmlEPTB;MUGuO|ExQSEQvF2=MYDTRW5ITVJ?
SW1573M1jWR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGnad3pKSzVyPUGxMlczQTVizszNM2nTWHNCVkeHUh?=
WM-115NGPr[WdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmOzTWM2OD1zMT63OVg5KM7:TR?=NHfVbolUSU6JRWK=
HuO9NEHQT2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M334WmlEPTB;MUGuPFc4PCEQvF2=MX;TRW5ITVJ?
YAPCM3\1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3vqVWlEPTB;MUGuPVI2QSEQvF2=NWHXeIdEW0GQR1XS
MDA-MB-453MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXK5O4J4UUN3ME2xNU46PTF3IN88US=>MWHTRW5ITVJ?
NCI-H596M{f4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXTJR|UxRTF{LkCzOlkh|ryPM{mwPHNCVkeHUh?=
A172NILVd4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MW\JR|UxRTF{LkC3PVgh|ryPM2LYdnNCVkeHUh?=
RS4-11NYHofoRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUDSSoRDUUN3ME2xNk4yPzJ3IN88US=>M3TFbnNCVkeHUh?=
HCC1937NXLDcIhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFvGSHhKSzVyPUGyMlc2PjRizszNMWLTRW5ITVJ?
SW837NGn4R49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoS3TWM2OD1zMj65NFI5KM7:TR?=MVPTRW5ITVJ?
NMC-G1M2XNZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX7JR|UxRTF{LkmyN|Qh|ryPMWHTRW5ITVJ?
PFSK-1M2nUZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRTF|LkC2JO69VQ>?MlO4V2FPT0WU
DBTRG-05MGNVK2SmVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkLXTWM2OD1zMz6wOlMzKM7:TR?=NGPkW5BUSU6JRWK=
SK-UT-1NFHWUHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX3JR|UxRTF|LkGwPFMh|ryPNV63d5J4W0GQR1XS
OVCAR-5NGmwVIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4HaOmlEPTB;MUOuNVU6OyEQvF2=MoK3V2FPT0WU
8505CMmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4L6[mlEPTB;MUOuNlA3PyEQvF2=NUC1c29TW0GQR1XS
SK-MEL-1MlnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH3WeFdKSzVyPUGzMlcyOzVizszNNFjD[2VUSU6JRWK=
LK-2NIjMTHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV3VRlNKUUN3ME2xN{44PjN7IN88US=>MYPTRW5ITVJ?
OE33Mn;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn[3TWM2OD1zMz63PFYh|ryPMomwV2FPT0WU
Ramos-2G6-4C10MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoDaTWM2OD1zND6wNlAzKM7:TR?=M4PyfHNCVkeHUh?=
EW-13NVT0PFN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYnRblUzUUN3ME2xOE4xOzV{IN88US=>M1LvPHNCVkeHUh?=
NCI-H1793NX;VdJg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmXDTWM2OD1zND6yNFg4KM7:TR?=NVnKPIdnW0GQR1XS
BHT-101NHPMRXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWfkRZJvUUN3ME2xOE4zPDFizszNNETKdYZUSU6JRWK=
RKOMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M176WGlEPTB;MUSuOVA4PSEQvF2=Mm\NV2FPT0WU
NEC8NHrFOJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHnVT5hKSzVyPUG0MlU1PzJizszNMnPzV2FPT0WU
PANC-10-05NUXZWVVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIq5NmhKSzVyPUG0MlYzPDdizszNNXn1dFM4W0GQR1XS
NCI-H2030NELMfWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3TxPGlEPTB;MUSuOlQ1QCEQvF2=M2TqPXNCVkeHUh?=
C2BBe1MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGXPV29KSzVyPUG0Mlc3PCEQvF2=M1rBXHNCVkeHUh?=
EM-2M{DXVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlnKTWM2OD1zND64OVc3KM7:TR?=NVv6V4k{W0GQR1XS
HCC1395NGi1NY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3zzPWlEPTB;MUSuPVM{QCEQvF2=MVLTRW5ITVJ?
A2058NIPwWolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1noemlEPTB;MUWuNFQxQSEQvF2=M{m2VHNCVkeHUh?=
SW1463MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUXjVXh{UUN3ME2xOU4xPDh3IN88US=>Ml;iV2FPT0WU
J82NV3ITHBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlrITWM2OD1zNT6wOVch|ryPMV;TRW5ITVJ?
CAL-120NE[0SG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWTJR|UxRTF3LkG0OFch|ryPMk\EV2FPT0WU
COLO-824NGH4dXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXPZeG05UUN3ME2xOU4yPTd7IN88US=>MlTyV2FPT0WU
LNCaP-Clone-FGCMkjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGrjOJJKSzVyPUG1MlQzPDhizszNNFjheGxUSU6JRWK=
CP66-MELMlS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4XrbmlEPTB;MUWuOFY5QCEQvF2=MU\TRW5ITVJ?
OC-314NIjuZldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXK4coZZUUN3ME2xOU41PzF2IN88US=>NHXSRVhUSU6JRWK=
OVCAR-8MnT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXK2Z3dlUUN3ME2xOU45QDZzIN88US=>NYH4VpJQW0GQR1XS
MFE-280NYCycZczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV3JR|UxRTF4LkC0PFgh|ryPMnvJV2FPT0WU
MHH-NB-11NILLWWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnTVTWM2OD1zNj6wPFM6KM7:TR?=NIj2dWpUSU6JRWK=
SW1990M3vGeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVLJR|UxRTF4LkG3OVUh|ryPM17DSnNCVkeHUh?=
U-266M1vR[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M37HOWlEPTB;MU[uNlI6QSEQvF2=MYLTRW5ITVJ?
MFM-223M2nkfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3PGfWlEPTB;MU[uN|k3PSEQvF2=MoDOV2FPT0WU
L-363MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIXKSYVKSzVyPUG2MlQ2PzdizszNMlThV2FPT0WU
MCF7NHXLTpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGnqfY9KSzVyPUG2MlQ4OjNizszNNXX2XXdiW0GQR1XS
SK-MEL-3NUPwVVl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFG1d|VKSzVyPUG2MlQ4QDdizszNM1m1cnNCVkeHUh?=
HHMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWDaNpRWUUN3ME2xOk42OTZ{IN88US=>NHi0VVhUSU6JRWK=
no-10MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHXQWG9KSzVyPUG2MlY{PDNizszNMX;TRW5ITVJ?
HuP-T3Mmq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXTIPGxqUUN3ME2xOk43PTd4IN88US=>M3nhRnNCVkeHUh?=
QIMR-WILNHToTldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXPJR|UxRTF4LkexNFUh|ryPMkfpV2FPT0WU
NCI-H1092M3LJeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEDINJdKSzVyPUG2Mlg{OTZizszNNH72fIVUSU6JRWK=
MZ2-MELNWjRe5JvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUHSVVQ3UUN3ME2xOk45PDB|IN88US=>NUL2VYx3W0GQR1XS
ES3Mnj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mmf0TWM2OD1zNj65NVM1KM7:TR?=MoTSV2FPT0WU
COLO-684NH\kboJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVvJR|UxRTF4Lkm0O|ch|ryPMYrTRW5ITVJ?
NCI-H661NFnUfoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkDjTWM2OD1zNj65Olk1KM7:TR?=NGTjUGZUSU6JRWK=
CP50-MEL-BMlP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1PJWGlEPTB;MUeuNFM1OyEQvF2=NGjlPVZUSU6JRWK=
NCI-H2405NIq3RZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYnCS201UUN3ME2xO{4yQTd2IN88US=>NXTQZ41IW0GQR1XS
U-2-OSNWPuRYlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmXOTWM2OD1zNz61N|A4KM7:TR?=NIrwe5VUSU6JRWK=
RERF-LC-MSMnvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYfyflh2UUN3ME2xO{42PTB6IN88US=>MlHSV2FPT0WU
NCI-H2342MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MljwTWM2OD1zNz61OVch|ryPM4nBXHNCVkeHUh?=
ES8NHm2OnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTF5Lk[wPFch|ryPM1XOPHNCVkeHUh?=
MOLT-16NUDybJFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF;6XFNKSzVyPUG3Mlg6OzRizszNMlLzV2FPT0WU
RH-18M3f4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI[1SlRKSzVyPUG4MlAxOzVizszNMoj1V2FPT0WU
D-283MEDMl3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{nSbmlEPTB;MUiuNFA5QCEQvF2=NXzBUllrW0GQR1XS
RCC10RGBM1voXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmfUTWM2OD1zOD6wOVU6KM7:TR?=MmTVV2FPT0WU
NCI-H1437Mn;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2HmTmlEPTB;MUiuNVY1OSEQvF2=NV7ZV2NbW0GQR1XS
SW982MnnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYnBcVNIUUN3ME2xPE4zPjdzIN88US=>NHHyW5JUSU6JRWK=
IST-MES1NGr4fFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWXJR|UxRTF6LkS0Nlgh|ryPNUX2Z4ZLW0GQR1XS
A704NWTtO5FtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkHkTWM2OD1zOD60O|U{KM7:TR?=MX3TRW5ITVJ?
ESS-1M2T5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTF6LkWyNFUh|ryPNVLOdXNjW0GQR1XS
SCHNF[1PYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mnu5TWM2OD1zOD62OFU3KM7:TR?=NHHGWZRUSU6JRWK=
COLO-320-HSRNFT0dFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIG2SY5KSzVyPUG4Mlc1PiEQvF2=MoHEV2FPT0WU
Mo-TMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIfCVVZKSzVyPUG4MlgzODRizszNMUfTRW5ITVJ?
Saos-2NGPNZXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3PqTWlEPTB;MUmuNVE3OiEQvF2=NWj1SmtUW0GQR1XS
SW684Mn6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MljZTWM2OD1zOT6xN|I3KM7:TR?=MnTvV2FPT0WU
KMOE-2M2rncmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2LGNmlEPTB;MUmuNlI1OiEQvF2=MnHSV2FPT0WU
MMAC-SFNWnISYhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkL5TWM2OD1zOT6yOlA4KM7:TR?=MlLrV2FPT0WU
JARMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoHmTWM2OD1zOT6yPVkh|ryPMYPTRW5ITVJ?
SK-MEL-28MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4DnR2lEPTB;MUmuN|M3OyEQvF2=NX;xOHBiW0GQR1XS
KNS-81-FDMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUnJR|UxRTF7LkW0Olgh|ryPM2ftT3NCVkeHUh?=
ES7MmjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVrJR|UxRTF7Lk[yPVIh|ryPNUn5dodyW0GQR1XS
AsPC-1NHvDXWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1HrSGlEPTB;MUmuOlQ4OSEQvF2=M3vnO3NCVkeHUh?=
NCI-H1155NF;Td3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmDDTWM2OD1zOT63NlM5KM7:TR?=NUT5dVNOW0GQR1XS
KYSE-510M1HieWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIfM[GNKSzVyPUG5Mlg4PDhizszNMYnTRW5ITVJ?
ES1MnjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3TSdWlEPTB;MUmuPVIyOyEQvF2=NGDz[YtUSU6JRWK=
PC-3NIjNPIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYfJR|UxRTF7Lkm2NFQh|ryPNXfR[XZsW0GQR1XS
GCTMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV\R[ZZUUUN3ME2yNE4{ODJ4IN88US=>NF3ESZRUSU6JRWK=
KARPAS-299M3HuUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTJyLkO0NlIh|ryPMlXrV2FPT0WU
DOHH-2MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1rFTWlEPTB;MkCuOVQ3OyEQvF2=NXLoZpFUW0GQR1XS
COLO-741NHPHZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkLXTWM2OD1{MD62OkDPxE1?NXLLZ|FnW0GQR1XS
NCI-H1395MnrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2K5NmlEPTB;MkCuOlY6PyEQvF2=Mon0V2FPT0WU
HCC1187M364emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3r1cGlEPTB;MkCuOlc{PCEQvF2=MXXTRW5ITVJ?
BeckerNXy1ZYl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXnMU2JDUUN3ME2yNE44OjBzIN88US=>M2Dke3NCVkeHUh?=
LU-134-AMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NI[5OmZKSzVyPUKxMlExOjZizszNNXL3eI5xW0GQR1XS
MKN45M1u3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnjLTWM2OD1{MT6xOVUyKM7:TR?=M1;nTnNCVkeHUh?=
LC-2-adNUXQNow1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlHBTWM2OD1{MT6yO|I6KM7:TR?=M2fWW3NCVkeHUh?=
EW-24NGnOOHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHrHb25KSzVyPUKxMlM6PDVizszNMXHTRW5ITVJ?
SK-N-ASMknQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYnJR|UxRTJzLkiyO|Yh|ryPNIrzSmJUSU6JRWK=
NCI-H2052MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRTJzLki5OlMh|ryPNX\2dnNGW0GQR1XS
A4-FukMkTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVLJR|UxRTJ{LkG0NVkh|ryPNEPzUnlUSU6JRWK=
NB10MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MY\JR|UxRTJ{LkKzO|Eh|ryPM1O1cHNCVkeHUh?=
CHP-212NEnw[FZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWq5OmM1UUN3ME2yNk4{OjJ{IN88US=>M4fEOXNCVkeHUh?=
KM12MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{DXWmlEPTB;MkKuN|U3KM7:TR?=NF\zeWRUSU6JRWK=
JEG-3NXjwVJlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnLtTWM2OD1{Mj6zO|gh|ryPMojWV2FPT0WU
LN-405M4izUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIrGdllKSzVyPUKyMlU6OTNizszNNVTUeWx6W0GQR1XS
HCT-15NYXafWZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{jPUWlEPTB;MkKuO|Q1OSEQvF2=NFTTcmJUSU6JRWK=
MLMAM{K0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUfDfJNiUUN3ME2yNk44PDdizszNM4TCXHNCVkeHUh?=
GI-1NUew[HROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIm0d5RKSzVyPUKyMlc3PThizszNMXTTRW5ITVJ?
RT-112M{XLNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3iwSGlEPTB;MkKuPFYyPiEQvF2=Mke4V2FPT0WU
MPP-89MkjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2jPbWlEPTB;MkKuPFY3OSEQvF2=NF;q[lJUSU6JRWK=
A3-KAWNFW3VYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH74[Y5KSzVyPUKzMlExODNizszNMlv2V2FPT0WU
KALS-1NF25PXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{LSZmlEPTB;MkOuNVQyPCEQvF2=M{LOeXNCVkeHUh?=
SF126MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFXrXnNKSzVyPUKzMlY6OjRizszNMV\TRW5ITVJ?
SiHaMl31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEfrcnJKSzVyPUKzMlk{OjdizszNM1rFS3NCVkeHUh?=
MDA-MB-415MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MonTTWM2OD1{Mz65OFk6KM7:TR?=NILqU4RUSU6JRWK=
DaoyMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlXCTWM2OD1{ND6xNlYh|ryPMl3OV2FPT0WU
COR-L23NYDCU2NpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1fYZmlEPTB;MkSuNVc3PyEQvF2=NIfn[|FUSU6JRWK=
KG-1M4DNdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4\JWWlEPTB;MkSuNVkzQCEQvF2=NVixSIRHW0GQR1XS
L-428NXKzZXBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1WzTGlEPTB;MkSuOVc6OSEQvF2=MkGxV2FPT0WU
NCI-H520NIDTZlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX;JR|UxRTJ2Lki4OlEh|ryPMmi3V2FPT0WU
COLO-792MlmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlHrTWM2OD1{NT6yO|MzKM7:TR?=MYjTRW5ITVJ?
NB12NYDBR41DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGnWfGdKSzVyPUK1MlI6PDdizszNMoPIV2FPT0WU
GAKNWDKSpdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoSzTWM2OD1{NT6yPVY{KM7:TR?=NFHYemtUSU6JRWK=
SW780MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmrZTWM2OD1{NT6zNlY1KM7:TR?=M4\6TnNCVkeHUh?=
GB-1NYjmfYJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIDrN25KSzVyPUK1MlQxPjlizszNM2j2XnNCVkeHUh?=
P12-ICHIKAWAMl;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVjIbpFRUUN3ME2yOU41Pzh3IN88US=>NWjFb41SW0GQR1XS
NCI-H1651MorSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF3ib4hKSzVyPUK1MlU6PyEQvF2=M2e0Z3NCVkeHUh?=
KE-37NXzXe|dwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{\sb2lEPTB;MkWuO|MyPSEQvF2=NILQdGpUSU6JRWK=
CCRF-CEMMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEPiU|ZKSzVyPUK1Mlk3PyEQvF2=NVTib5pXW0GQR1XS
SF295NVn1epB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXL3WpJPUUN3ME2yOk4xPDJ3IN88US=>MWjTRW5ITVJ?
G-361NG\DcHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2myPGlEPTB;Mk[uNVAzPyEQvF2=MnPTV2FPT0WU
HOP-92Mo\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnLXTWM2OD1{Nj6xNlI3KM7:TR?=NWfIO3U6W0GQR1XS
UMC-11NUH1fIlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXn3cIZ1UUN3ME2yOk41PTF2IN88US=>Ml:0V2FPT0WU
IST-SL1NX7wUJQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTJ4Lk[1PVEh|ryPM3PoXXNCVkeHUh?=
TE-11MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWHJR|UxRTJ4Lke3OVIh|ryPNYDtZpY4W0GQR1XS
NCI-H1304NWXKcG9{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV[xRZZqUUN3ME2yOk46OTB6IN88US=>MVjTRW5ITVJ?
SJSA-1MlW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY\JNJlSUUN3ME2yO{4xOTd4IN88US=>M3TBc3NCVkeHUh?=
BCPAPMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFy2WItKSzVyPUK3MlE{PyEQvF2=Mkf3V2FPT0WU
HTC-C3MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1vNfGlEPTB;MkeuNlU3OSEQvF2=M{K1dnNCVkeHUh?=
EW-16M{LMc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4DNTGlEPTB;MkeuNlk1PyEQvF2=MXvTRW5ITVJ?
HT-144MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEjrO5FKSzVyPUK3MlQxOzJizszNMlfoV2FPT0WU
MHH-ES-1MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXTJR|UxRTJ5LkS0OFch|ryPMYXTRW5ITVJ?
T98GNH;3[WZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIPE[oJKSzVyPUK3MlU5PDZizszNNWjiRVFnW0GQR1XS
RPMI-8866MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3zmd2lEPTB;MkeuO|U3OiEQvF2=NELWTVRUSU6JRWK=
BENM{ezfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFjkVJZKSzVyPUK3Mlg2OTdizszNNUPkN5lNW0GQR1XS
MDA-MB-231NIDEeolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXzJR|UxRTJ6LkK3PVUh|ryPM{jjc3NCVkeHUh?=
HuH-7NWi2fZJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWrJR|UxRTJ6LkSwNlgh|ryPM{S1N3NCVkeHUh?=
SK-N-FINFTOV2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2fVR2lEPTB;MkiuOFM{KM7:TR?=MW\TRW5ITVJ?
AN3-CAM{j5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVLqOY5oUUN3ME2yPE41Ozl3IN88US=>NUTpd|FlW0GQR1XS
EGI-1M2\oOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEfaV5BKSzVyPUK4MlU6OjhizszNMUnTRW5ITVJ?
697NGDCZo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWD2fnlRUUN3ME2yPE43OzNzIN88US=>M3ixTXNCVkeHUh?=
TCCSUPNVryUHc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWLHWIdMUUN3ME2yPE43PDF6IN88US=>MV\TRW5ITVJ?
GR-STNUfQWolxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkPmTWM2OD1{OD62Olk3KM7:TR?=MljOV2FPT0WU
SK-N-DZM2O5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1vsbWlEPTB;MkiuOlg5PSEQvF2=Mnr4V2FPT0WU
MIA-PaCa-2NWn6VIc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTJ6Lke5OVkh|ryPMYHTRW5ITVJ?
IGR-1M4TtdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkfoTWM2OD1{OD64PFc1KM7:TR?=MmTqV2FPT0WU
BFTC-905MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHnhdpBKSzVyPUK5MlI4ODVizszNMnnwV2FPT0WU
NCI-H1581MlnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHWwT4hKSzVyPUK5MlMyPDVizszNNXTMdYFFW0GQR1XS
RDNXXH[odVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRTJ7LkWyN|Mh|ryPMVPTRW5ITVJ?
SF268NGSwU5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWrJR|UxRTJ7LkW5N|Eh|ryPMXrTRW5ITVJ?
SHP-77NF:zbpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3y3T2lEPTB;MkmuOlE5OiEQvF2=NWruend6W0GQR1XS
D-566MGM4XIbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MknMTWM2OD1{OT65N|k{KM7:TR?=MlzDV2FPT0WU
TGBC1TKBNULs[lR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3PPSmlEPTB;M{CuNVI{QCEQvF2=NX\NdHVOW0GQR1XS
MEL-HONV7hZ3YxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFHwNJdKSzVyPUOwMlE1OjNizszNMUXTRW5ITVJ?
SJRH30MonxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV7JR|UxRTNyLkKxNFgh|ryPMVTTRW5ITVJ?
D-336MGMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTNyLkK4PVIh|ryPNYiwV3VZW0GQR1XS
C3ANF74UGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3TyPGlEPTB;M{CuNlkzPyEQvF2=MnrzV2FPT0WU
Calu-6NG[1eoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXmxXoNzUUN3ME2zNE4zQTZ|IN88US=>MoXwV2FPT0WU
MZ1-PCM4Xh[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFzZR2xKSzVyPUOwMlM6OyEQvF2=MnPmV2FPT0WU
KYSE-70NUDONHBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3jp[WlEPTB;M{CuOVEyPCEQvF2=MXfTRW5ITVJ?
CAPAN-1MnK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3jmU2lEPTB;M{CuOVE5OSEQvF2=NEfRfYdUSU6JRWK=
DK-MGM2HKb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGraZmxKSzVyPUOwMlU1PTZizszNNWTvemplW0GQR1XS
SK-HEP-1NYPJS3lGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1P4dWlEPTB;M{CuOlMzPiEQvF2=M2\IPXNCVkeHUh?=
MS-1MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4jhdmlEPTB;M{CuPFg5QSEQvF2=M4TacHNCVkeHUh?=
GI-ME-NM4\xWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NE[3eXJKSzVyPUOxMlA2PzFizszNMVnTRW5ITVJ?
NCI-H510AMl[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3XrOGlEPTB;M{GuOFAxPiEQvF2=NIjhfmlUSU6JRWK=
NB17NGHmT4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYfB[XoyUUN3ME2zNU42OTh3IN88US=>MVzTRW5ITVJ?
639-VMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{PybGlEPTB;M{GuOVI1OyEQvF2=MWrTRW5ITVJ?
CAL-51NF\EcZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\VW406UUN3ME2zNU42PjZ5IN88US=>MVfTRW5ITVJ?
HGC-27M{jn[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NETLTlNKSzVyPUOxMlU5PzNizszNMVzTRW5ITVJ?
GOTONXL1OGsyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4XVRmlEPTB;M{GuPFUxPiEQvF2=MlfuV2FPT0WU
ChaGo-K-1NGLFPWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXHUUlkxUUN3ME2zNk4xODdizszNNWLyRYF7W0GQR1XS
RO82-W-1NFPtNWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MknoTWM2OD1|Mj6xOlA1KM7:TR?=MUHTRW5ITVJ?
SH-4MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWfzOmo5UUN3ME2zNk4yQDV6IN88US=>NEfsRZdUSU6JRWK=
A204MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTN{LkWwOlkh|ryPNHHr[4ZUSU6JRWK=
DMS-273M2\acmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3r0ZWlEPTB;M{KuOVMzOiEQvF2=M3zoN3NCVkeHUh?=
KGNNGDjVYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3XXWWlEPTB;M{KuOlM{KM7:TR?=NYTrUWN[W0GQR1XS
SK-MEL-2MnTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF\xd5pKSzVyPUOyMlY2OjdizszNMmLQV2FPT0WU
NCI-H2228NUfuW3BYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUSzXW9RUUN3ME2zNk43PjB{IN88US=>M2LKSXNCVkeHUh?=
MKN28NXfDdY02T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWmzUpBkUUN3ME2zNk44QDN6IN88US=>MkLlV2FPT0WU
H-EMC-SSMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIW4XplKSzVyPUOyMlk3PzhizszNM{iyWHNCVkeHUh?=
ATN-1NWLydVczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH3qbotKSzVyPUOzMlE1OTZizszNNWDVUm52W0GQR1XS
D-263MGMnzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVf2bZFEUUN3ME2zN{45Ozd6IN88US=>NIXOSXFUSU6JRWK=
LU-135MmnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEewVo1KSzVyPUOzMlg5OjlizszNM1\FcnNCVkeHUh?=
C8166Ml;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2X4SWlEPTB;M{OuPFg2PCEQvF2=Ml;4V2FPT0WU
T-24M17QOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH;Gb25KSzVyPUO0MlAzODVizszNNFjw[45USU6JRWK=
MewoMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEWzbmtKSzVyPUO0MlE{PDlizszNM{TQWHNCVkeHUh?=
22RV1NYfNWVZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYXJR|UxRTN2LkG3OVQh|ryPMkj6V2FPT0WU
KM-H2NUXMRYxrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnrKTWM2OD1|ND6xO|c6KM7:TR?=NWjJUItNW0GQR1XS
NCI-H2122MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYDMRoFWUUN3ME2zOE4{PDdzIN88US=>Mn7EV2FPT0WU
ABC-1MmW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWDJR|UxRTN2LkO2PVMh|ryPNHG4O|BUSU6JRWK=
NCI-H1355NUH4bJc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWfJR|UxRTN2LkO4PFkh|ryPMYnTRW5ITVJ?
NOMO-1NGDr[oNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXrQVo1QUUN3ME2zOE42PzB|IN88US=>NIrGR21USU6JRWK=
MZ7-melM3TjRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2LwSWlEPTB;M{SuOlQ5PyEQvF2=M1TtT3NCVkeHUh?=
NCI-H810MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVHJR|UxRTN2LkeyO|gh|ryPMkPDV2FPT0WU
D-392MGMle5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYDENYttUUN3ME2zOU4xPTZ3IN88US=>MlrSV2FPT0WU
LB771-HNCMnv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRTN3LkG2OVgh|ryPNHrUSFdUSU6JRWK=
COLO-679MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4\zOmlEPTB;M{WuN|g5KM7:TR?=MXvTRW5ITVJ?
SK-PN-DWM1Xuc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV3GSJpNUUN3ME2zOU41OzZ7IN88US=>MXzTRW5ITVJ?
VA-ES-BJMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXHtcJh5UUN3ME2zOU41PjR7IN88US=>MY\TRW5ITVJ?
KNS-42NWC1cItWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYLJR|UxRTN3LkW4NlYh|ryPNYrWdGFbW0GQR1XS
RVH-421NXK2W25uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH:xV4RKSzVyPUO1Mlc3PDVizszNM3XDdHNCVkeHUh?=
P30-OHKMn7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTN3Lki3OVIh|ryPMm\5V2FPT0WU
G-402NFXBVJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXfJR|UxRTN3Lkm4Olch|ryPMlvEV2FPT0WU
S-117MnnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkH6TWM2OD1|Nj6zNFA5KM7:TR?=M4fMPHNCVkeHUh?=
RXF393MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVLJR|UxRTN4LkO3PFUh|ryPMX3TRW5ITVJ?
LCLC-103HNIHxS4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1PiXmlEPTB;M{[uO|gxOyEQvF2=MnPXV2FPT0WU
U-118-MGM{PCOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3XsTGlEPTB;M{[uPFg1PyEQvF2=M4XFSXNCVkeHUh?=
8-MG-BAMorJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWXLdpl4UUN3ME2zOk46PDh|IN88US=>MmnXV2FPT0WU
MFH-inoMWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkjUTWM2OD1|Nz6zN|cyKM7:TR?=MorIV2FPT0WU
NCI-H23Mkn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXznW|lrUUN3ME2zO{41OTl4IN88US=>NGHGVmNUSU6JRWK=
NCI-H446NX\kcIZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\FPFQ{UUN3ME2zO{41QDZ{IN88US=>MlvwV2FPT0WU
LU-99ANHvQW5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX;3eoZzUUN3ME2zO{42PzNzIN88US=>Moj2V2FPT0WU
KP-N-YNNX\oflB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmD3TWM2OD1|Nz62NVk2KM7:TR?=M37rOHNCVkeHUh?=
SCC-9MkfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2mxZWlEPTB;M{euO|g{QCEQvF2=MVPTRW5ITVJ?
EFM-19MkjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXXJR|UxRTN5Lke5Olch|ryPNXfxeHNQW0GQR1XS
A427M2DWe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MknQTWM2OD1|Nz65NVA4KM7:TR?=MX;TRW5ITVJ?
LB831-BLCM1rBXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn7nTWM2OD1|OD62NFM6KM7:TR?=MkPyV2FPT0WU
HOSMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIXqVVJKSzVyPUO5MlYzPzNizszNNEH0V5lUSU6JRWK=
LAN-6NXjPTHB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTRyLkCxNVIh|ryPMnTFV2FPT0WU
U251NFzKSZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF;6OWRKSzVyPUSwMlQxPTRizszNNFHtU|hUSU6JRWK=
SNU-387NGe0dJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXJR|UxRTRyLkS1OVMh|ryPMVfTRW5ITVJ?
DMS-79NUHZSoNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2LJfWlEPTB;NECuOVg5QSEQvF2=NVTxRVZUW0GQR1XS
SK-LU-1MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml3MTWM2OD12MD62OVY5KM7:TR?=M1jZOnNCVkeHUh?=
HTNFfHflBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX\JR|UxRTRyLk[2N|kh|ryPMl\DV2FPT0WU
KP-N-YSNGrKNZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTRyLk[3Olgh|ryPMXjTRW5ITVJ?
DMS-114MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkfyTWM2OD12MD64N|c1KM7:TR?=NVXy[4VsW0GQR1XS
HUTU-80MmHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWDxcGFvUUN3ME20NU4xPTZ7IN88US=>MYTTRW5ITVJ?
ONS-76NVHOWo5LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlW4TWM2OD12MT60O|A6KM7:TR?=NYGyWGo1W0GQR1XS
A673M1f1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3HkZ2lEPTB;NEGuOVE2PyEQvF2=MUjTRW5ITVJ?
HPAF-IINV;3VWYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXL6OHJkUUN3ME20NU43PzB7IN88US=>NW\4ZlZvW0GQR1XS
UACC-257MorzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmjMTWM2OD12MT63N|Y6KM7:TR?=MoG1V2FPT0WU
EW-22NVPRR4Y1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmXVTWM2OD12MT64Olk4KM7:TR?=M1vNUHNCVkeHUh?=
NCI-H1755MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWrQT3pxUUN3ME20NU45PzJ3IN88US=>MULTRW5ITVJ?
KYSE-150NVO0TGtVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFLUeGFKSzVyPUSyMlE4QDJizszNM3PxeXNCVkeHUh?=
CGTH-W-1M3[3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV7JR|UxRTR{LkS5OVUh|ryPNF3C[o9USU6JRWK=
NB13MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUHJR|UxRTR{Lk[yNVch|ryPM1rGWHNCVkeHUh?=
SW872M2\vOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlT5TWM2OD12Mj62N|MyKM7:TR?=NEDoXI5USU6JRWK=
KP-4NX23ZWh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGnFRo5KSzVyPUSyMlg5OzJizszNM1z4OHNCVkeHUh?=
HCC38MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1K2b2lEPTB;NEKuPVYyQCEQvF2=MoDxV2FPT0WU
BB49-HNCM3X0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF3ON3VKSzVyPUSzMlI{PTZizszNNGD4VZpUSU6JRWK=
CAL-62NYrvNlViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHqx[W5KSzVyPUSzMlQxOjhizszNMXHTRW5ITVJ?
NCI-H2029M4PJSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXjZcYVKUUN3ME20N{42PThzIN88US=>NH7zO4xUSU6JRWK=
M14MmDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXnzUYxsUUN3ME20OE4yOzN{IN88US=>MnnvV2FPT0WU
COLO-680NNIC3XXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmLCTWM2OD12ND6zN|kh|ryPNXLtdm9tW0GQR1XS
Hs-578-TMle4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUDJR|UxRTR3LkCyPVQh|ryPNYK0XZU6W0GQR1XS
MSTO-211HM4HDS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXzDcY12UUN3ME20OU46PDh{IN88US=>MUfTRW5ITVJ?
EW-1MlvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVzpNXVjUUN3ME20OU46Pjh7IN88US=>NImyXIpUSU6JRWK=
SW948MljmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2TWNmlEPTB;NE[uOFQ3OiEQvF2=NEC3VXNUSU6JRWK=
NCI-H460MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYDJR|UxRTR4LkWyN{DPxE1?MX7TRW5ITVJ?
CAS-1NFvGNWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1PuWGlEPTB;NE[uO|cxOSEQvF2=MnfsV2FPT0WU
TGBC11TKBM{jJe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml[2TWM2OD12Nz6xO|c4KM7:TR?=MVfTRW5ITVJ?
HD-MY-ZMkjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHTnfFJKSzVyPUS4Mlc5PiEQvF2=MmXKV2FPT0WU
NCI-H226NFPURZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEexVFdKSzVyPUS5Mlc4QDVizszNMoDjV2FPT0WU
PA-1MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVnZepM4UUN3ME20PU45OzN3IN88US=>NGjve2lUSU6JRWK=
LB2518-MELMnPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTR7Lki3NlMh|ryPNHKyTJRUSU6JRWK=
A101DMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1:ydmlEPTB;NEmuPVQzPSEQvF2=NI\OSWRUSU6JRWK=
NCI-H2087MmLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFrhUmZKSzVyPUS5Mlk3QDJizszNMXPTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Daily oral administration of BIBW2992 at 20 mg/kg for 25 days results in dramatic tumor regression with a cumulative treated/control tumor volume ratio (T/C ratio) of 2%. Reduced phosphorylation of EGFR and AKT is confirmed by immunohistochemical staining of tissue sections. Therefore, like lapatinib and neratinib, BIBW2992 is a next generation tyrosine kinase inhibitor (TKI) that inhibits human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases irreversibly. BIBW2992 is not only active against EGFR mutations targeted by first generation TKIs like Erlotinib or Gefitinib, but also against those insensitive to these standard therapies. [1]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

In vitro kinase activity assays The wild type tyrosine kinase domain of the human EGFR as well as that of the EGFR L858R/T790M double mutant are fused to Glutathione-S-transferase (GST), and extracted. Enzyme activity is then assayed in the presence of the inhibitor BIBW2992, serially diluted in 50% DMSO. A random polymer pEY (4:1) is used as substrate and biotinylated pEY (bio-pEY) is added as a tracer substrate. The kinase domain of HER2 is cloned using the baculovirus system and extracted similarly to that of EGFR kinase. Details of assays for EGFR, HER2, SRC, BIRK and VEGFR2 kinase activity are available in Supplementary information.

Cell Assay:

[1]

Cell lines NSCLC cells
Concentrations 0-10 μM
Incubation Time 1 hour
Method

1 × 104 NSCLC cells are transferred into each well of a 96-well plate and cultured overnight in serum-free media for the EGFR phosphorylation assay. After addition of BIBW2992 on the next day, the plates are incubated at 37 °C for 1 hour. EGF-stimulation is done using 100 ng/mL for 10 min at room temperature. Cells are washed with ice cold PBS, extracted with 120 μL HEPEX buffer per well and shaken at room temperature for 1 hour. In all 2 × 104 cells per well is used for the HER2 phosphorylation assay. Streptavidin precoated plates are coated with anti-EGFR-biotin at 1:100 dilution in blocking buffer and c-erb2/HER2 oncoprotein Ab-5(Clone N24)-Biotin. Cell extracts is then transferred to the antibody-coated wells and incubated at room temperature for 1 hour. Extinction is measured at 450 nm.

Animal Study:

[1]

Animal Models Athymic NMRI-nu/nu female mice
Formulation In 0.5% methocellulose-0.4% polysorbate-80 (Tween 80)
Dosages 20 mg/kg
Administration Oral administration

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Li D, et al. Oncogene, 2008, 27(34), 4702-4711.

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-04-16)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02183883 Not yet recruiting Non-small Cell Lung Cancer University College, London|Boehringer Ingelheim May 2016 Phase 2
NCT02716311 Not yet recruiting Non Small Cell Lung Cancer Intergroupe Francophone de Cancerologie Thoracique April 2016 Phase 2
NCT02501603 Not yet recruiting Gastric Cancer|Gastroesophageal Junction Cancer Yonsei University March 2016 Phase 2
NCT02629523 Not yet recruiting Lung Neoplasms|EGFR Gene Mutation Chonnam National University Hospital March 2016 Phase 2
NCT02695290 Recruiting Carcinoma, Non-Small-Cell Lung|ErbB Receptors Boehringer Ingelheim March 2016 Phase 4

view more

Chemical Information

Download Afatinib (BIBW2992) SDF
Molecular Weight (MW) 485.94
Formula

C24H25ClFN5O3

CAS No. 439081-18-2
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 97 mg/mL (199.61 mM)
Ethanol 15 mg/mL (30.86 mM)
Water <1 mg/mL (<1 mM)
In vivo 0.5% methylcellulose/0.2% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name (S,E)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide

Customer Product Validation (3)


Click to enlarge
Rating
Source Int J Proteomics 2011 2011, 215496. Afatinib (BIBW2992) purchased from Selleck
Method CEER assay
Cell Lines H460/A549/RFU cell lines
Concentrations 0-10 μM
Incubation Time 4 h
Results This data showed that a potent dose-dependent inhibition of the HER1 and HER2 pathways in the HCC827 cells was observed by treatment with BIBW-2992. Other HER1 and/or HER2 pathway-activated cell lines, H1975 and H1650, were likewise had these pathway activations blocked by the treatment with BIBW-2992.

Click to enlarge
Rating
Source Int J Proteomics 2011 2011, 215496. Afatinib (BIBW2992) purchased from Selleck
Method Nikon inverted-phase microscope
Cell Lines lung tumor cell lines
Concentrations 0.1/1 µM
Incubation Time two weeks
Results Reduction of cell colony size formation was observed by the treatment with the irreversible HER1/2 inhibitor BIBW-2992 in H1975 and H1650 cells as seen when these cells were grown in an anchorage-dependent manner.

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. Afatinib (BIBW2992) purchased from Selleck
Method Western blot
Cell Lines Breast cancer cells
Concentrations 0-1 nM
Incubation Time 3 h
Results BIBW2992 treatment resulted in a reduction of EGFR phosphorylation in Breast cancer cells.

Product Use Citation (34)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related EGFR Products

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • Afatinib (BIBW2992) Dimaleate

    Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.

  • Poziotinib (HM781-36B)

    Poziotinib (HM781-36B) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Phase 2.

  • Gefitinib (ZD1839)

    Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

    Features:A potent EGFR tyrosine kinase inhibitor.

  • Erlotinib HCl (OSI-744)

    Erlotinib HCl (OSI-744) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • Osimertinib (AZD9291)

    Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.

  • Lapatinib

    Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.

  • AG-490 (Tyrphostin B42)

    AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.

  • Rociletinib (CO-1686, AVL-301)

    Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT in cell-free assays, respectively. Phase 2.

  • AG-1478 (Tyrphostin AG-1478)

    AG-1478 (Tyrphostin AG-1478) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.

Recently Viewed Items

Tags: buy Afatinib (BIBW2992) | Afatinib (BIBW2992) ic50 | Afatinib (BIBW2992) price | Afatinib (BIBW2992) cost | Afatinib (BIBW2992) solubility dmso | Afatinib (BIBW2992) purchase | Afatinib (BIBW2992) manufacturer | Afatinib (BIBW2992) research buy | Afatinib (BIBW2992) order | Afatinib (BIBW2992) mouse | Afatinib (BIBW2992) chemical structure | Afatinib (BIBW2992) mw | Afatinib (BIBW2992) molecular weight | Afatinib (BIBW2992) datasheet | Afatinib (BIBW2992) supplier | Afatinib (BIBW2992) in vitro | Afatinib (BIBW2992) cell line | Afatinib (BIBW2992) concentration | Afatinib (BIBW2992) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us